Mobile website
Archive > Volume 22 Issue 6 > 2015,22(6):734-739. DOI:10.3872/j.issn.1007-385X.2015.06.010 Prev Next
Clinical Research
Clinical signficance of EGFR, KRAS, BRAF and PIK3CA gene mutations in 430 Chinese patients with non-small cell lung cancer
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To provide guide for the clinical medication of EGFR-tyrosine kinase inhibitors (TKIs) and discussion of their association with clinical pathological features, we investigated the amplification and mutation status of genes encoding epidermal growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene homolog (KRAS), B-Raf proto oncogene serine/threonine protein kinase (BRAF) and phosphatidylinositol -4，5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) in NSCLC patients.Methods:EGFR, KRAS, BRAF and PIK3CA mutations in 430 randomly selected Chinese patients with NSCLC were analyzed by SurPlex-xTAG70plex platform. The relationship between the mutations and the clinicopathologic features was further evaluated.Results: The mutation rates of EGFR, KRAS, BRAF and PIK3CA were 41.2%, 7.9%, 0.7%, and 3.7% respectively in these patients. The mutation rates of EGFR exon 19 and 21 were higher in females than those in males (P<0.01), significantly increased in adenocarcinomas compared to those in the other forms of lung cancers (P<0.01), and risen markedly in non-smokers compared to those in smokers (P<001). Conversely, the KRAS mutation rates were higher in males than those in females (P<0.05), increased significantly in adenocarcinomas compared to those in the other forms of lung cancers (P<0.005), and risen markedly in smokers compared to those in non-smokers (P<0.01). The PIK3CA mutation rates were significantly lower in adenocarcinomas compared to those in the other forms of lung cancers (P<0.01). Conclusion: The mutation rates of EGFR and KRAS in NSCLC are associated with gender, pathohistology, and smoking habits. Concurrent presence of EGFR and KRAS mutations was found in NSCLC from these patients, and the mutational statuses of PIK3CA and EGFR or KRAS were not mutually exclusive.
Keywords:
Project Supported:
Project supported by the Heigh-tech District and Incubation System Construction Field Foundation of Guangdong Provincial Department of Science and Technology (No. 2014B010108005)
Clc Number:
